Cilomilast GlaxoSmithKline.
GlaxoSmithKline is developing cilomilast, a phosphodiesterase 4 inhibitor, for the potential treatment of chronic obstructive pulmonary disease. The compound has been assessed in phase III clinical trials.
Brown
William M
WM
Paddock Laboratories Inc, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com
D000818:Animals; D002264:Carboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004345:Drug Industry / Q000458:organization & administration; D006801:Humans; D015201:Meta-Analysis as Topic; D009570:Nitriles / Q000494:pharmacology* / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
D002264:Carboxylic Acids; D003509:Cyclohexanecarboxylic Acids; D009570:Nitriles; C433247:Cilomilast